3 Dividend Kings to Buy in November and Never Sell

The article recommends AbbVie, Abbott Laboratories and Coca-Cola as long-term dividend stocks, citing dividend-increase streaks of 55 years for AbbVie and 64 years for Coca-Cola. AbbVie’s Skyrizi and Rinvoq have exceeded expectations, with no U.S. patent cliff expected before 2033; Abbott closed its $21 billion cash acquisition of Exact Sciences and plans to spin off its nutrition business. Coca-Cola recently reached an all-time high, though the article expects generally modest top- and bottom-line growth.

Analysis

The “Dividend King” label is a weak timing signal: it says little about entry valuation, and AbbVie’s cited streak includes years before it was a standalone issuer. Treat this as a quality screen, not evidence of durable excess returns.

Over 1–3 months, the key differentiator is execution, not payout history. For AbbVie, the market must see newer products offsetting legacy-product erosion; pipeline failures or slower uptake would expose the dividend narrative to a tougher earnings bridge. The 2033 U.S. patent timing cited for Skyrizi and Rinvoq is not protection against nearer-term competitive or pricing pressure. For Abbott, Exact Sciences integration and the nutrition separation could sharpen the portfolio, but also create execution costs and obscure underlying growth during transition. FreeStyle Libre’s addressable-market estimate is not a forecast of adoption: Dexcom and other CGM competitors, reimbursement, and patient uptake determine conversion. Verify acquisition funding, separation terms, and segment-level guidance before underwriting a rerating.

At 6–18 months, Coca-Cola’s defensive demand can help relative performance, but a stock near a record high may be more sensitive to valuation compression if volume growth weakens or price increases meet consumer resistance. The article supplies no valuation, yield, or updated guidance data, so it does not establish attractive risk/reward. Falsifiers: AbbVie product-growth/guidance deceleration; Abbott CGM growth or integration disappointments; KO volume weakness alongside slower pricing. No immediate trade is justified by the promotional framing alone.

Key Decisions for Investors

• Do not buy solely on dividend streaks. Before initiating ABBV or KO, compare forward valuation and cash dividend coverage with historical ranges; those data are absent here.
• Put ABBV on a catalyst watch: require evidence that Skyrizi/Rinvoq growth and launches offset erosion in older products. Reassess on guidance or product-sales deterioration rather than relying on distant patent dates.
• For ABT, monitor Exact Sciences integration costs, acquisition funding, nutrition separation terms, and Libre adoption versus Dexcom. Consider a position only after segment disclosures clarify organic growth and capital allocation.
• No immediate position in KO from this article. If volume trends weaken while pricing moderates, reassess downside versus the defensive premium; a sustained volume recovery would falsify that concern.